Generic Medicine Info
May be taken with or without food.
Severe respiratory depression, bronchial asthma (in the absence of resuscitative equipment or with unmonitored settings), hypercabia, known or suspected gastrointestinal obstruction, paralytic ileus, ulcerative colitis, biliary or renal tract spasm, increased intracranial pressure, head injury, acute alcoholism, severe hepatic impairment; patient under coma. Concurrent use of or within 14 days of discontinuing MAOIs.
Special Precautions
Patient with CV disease (e.g. acute MI, cardiac hypertrophy), hypovolaemia, COPD, adrenocortical insufficiency (e.g. Addison's disease), seizures, delirium tremens, mental health disorders (e.g. depression, anxiety disorders, posttraumatic stress disorder), psychosis, prostatic hyperplasia, thyroid dysfunction, electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia). Elderly, debilitated, and obese patients. Renal and hepatic impairment. Pregnancy and lactation. Avoid abrupt withdrawal. Patient CounsellingThis drug may cause drowsiness, if affected, do not drive or operate machinery. Monitoring Parameters Screen patient for any physical or psychological dependence before treatment. Obtain baseline ECG and monitor for QTC prolongation. Routinely check blood pressure, CNS status, respiratory status, and degree of sedation. Assess for signs of misuse, abuse, or addiction, respiratory depression, and serotonin syndrome.
Adverse Reactions
Significant: QT prolongation, serious arrhythmias (e.g. torsade de pointes), severe hypotension, serotonin syndrome, constipation, secondary hypogonadism leading to mood disorders and osteoporosis (long term use), severe elevation of intracranial pressure, seizures, sleep related disorders (e.g. central sleep apnoea [CSA], hypoxaemia), Oddi constriction. Ear and labyrinth disorders: Vertigo. Eye disorders: Blurred vision, miosis. Gastrointestinal disorders: Nausea, vomiting, dry mouth. General disorders and administration site conditions: Fatigue, injection site pain, erythema, and swelling. Investigations: Increased weight. Metabolism and nutrition disorders: Fluid retention. Nervous system disorders: Sedation, dizziness, drowsiness, light-headedness, confusion. Psychiatric disorders: Euphoria, hallucinations. Skin and subcutaneous tissue disorders: Rash, pruritus, urticaria, diaphoresis.
Potentially Fatal: Respiratory depression.
Drug Interactions
Increased serum concentrations with CYP3A4 inhibitors (e.g. clarithromycin, erythromycin, delavirdine, fluconazole, itraconazole, ketoconazole, fluoxetine, fluvoxamine). Decreased serum concentrations with CYP3A4 inducers (e.g. barbiturates, carbamazepine, phenytoin, nevirapine, rifampicin, efavirenz, amprenavir, spironolactone, dexamethasone). Increased risk of QT prolongation with antiarrhythmics (e.g. sotalol, amiodarone), antipsychotics (e.g. thioridazine, haloperidol, sertindole, phenotiazines), antidepressants (e.g. paroxetine, sertraline). Increased risk of serotonin syndrome with SSRIs, SNRIs and TCAs.
ATC Classification
N07BC02 - methadone ; Belongs to the class of drugs used in the management of opioid dependence.
Disclaimer: This information is independently developed by CIMS based on methadone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in